A5019412793- Ferroptosis and cancer prognosis
- Chromatin Remodeling and Cancer
- Advanced Breast Cancer Therapies
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Advanced biosensing and bioanalysis techniques
- Plasma Applications and Diagnostics
- Advanced Nanomaterials in Catalysis
- RNA Interference and Gene Delivery
- Heme Oxygenase-1 and Carbon Monoxide
- Nanoparticle-Based Drug Delivery
- Advancements in Transdermal Drug Delivery
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Cancer, Stress, Anesthesia, and Immune Response
- Immune cells in cancer
- Skin Protection and Aging
- Immunotherapy and Immune Responses
- Advanced Drug Delivery Systems
- Adenosine and Purinergic Signaling
- Advanced Fiber Optic Sensors
- Extracellular vesicles in disease
- MicroRNA in disease regulation
McGill University
2022-2025
McGill University Health Centre
2025
Shanghai Jiao Tong University
2019-2022
Abstract Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in NSCLC cells. Inhibition BRD4, either by...
Abstract Ferritin internalized into tumor cells is degraded and releases iron ions via ferritinophagy. Iron participate in Fenton reaction to produce reactive oxygen species for lipid peroxidation ferroptosis. Inhibition of indoleamine‐2,3‐dioxygenase (IDO) decreases tryptophan elimination induce T activation immunosuppression relief. The active targeting nanoparticles containing ferritin a pH‐sensitive molecular‐switch (FPBC@SN) are developed utilize ferritinophagy‐cascade ferroptosis...
Extracellular matrix (ECM) accumulating in the tumor microenvironment (TME) is generated by tumor-associated fibroblasts. It can elevate interstitial fluid pressure and form dense barriers tissues. Consequently, nanocarriers are hindered from permeating into deeper sites. Thus, programmed drug-releasing nanoparticles, G(TM)PPSP, were developed for TME remodeling breast cancer therapy. Gelatin nanoparticles linked with platinum (PtNPs) to obtain G(TM)PPSP a size of 214.0 ± 5.0 nm. Telmisartan...
Cold atmospheric plasma (CAP) is a unique form of physical that has shown great potential for cancer therapy. CAP uses ionized gas to induce lethal oxidative stress on cells; however, the efficacy therapy continues be improved. Here, we report an injectable hydrogel-mediated approach enhance anti-tumor by regulating phosphorylation eIF2α. We discovered reactive oxygen and nitrogen species (ROS/RNS), two main components in CAP, can lead tumor cells. Elevated subsequently induces eIF2α...
Cold atmospheric plasma (CAP) has exhibited exciting potential for cancer treatment. Reactive oxygen and nitrogen species (RONS), the primary constituents in CAP, contribute to cell death by elevating oxidative stress cells. However, several intrinsic cellular antioxidant defense systems exist, such as glutathione peroxidase 4 (GPX4) enzyme, which dampens cell-killing efficacy of CAP. RAS-selective lethal 3 (RSL3), also known a ferroptosis inducer, is synthetic GPX4 inhibitor. Therefore, we...
Immune checkpoint blockade (ICB) therapy is a revolutionary approach to treat cancers, but still have limited clinical applications. Accumulating evidence pinpoints the immunosuppressive characteristics of tumor microenvironment (TME) as one major obstacle. The TME, characterized by acidity, hypoxia and elevated ROS levels, exerts its detrimental effects on infiltrating anti-tumor immune cells. Here, we developed TME-responsive immunotherapeutic catalase-loaded calcium carbonate...
P@P/H NPs were rapidly disintegrated in response to ROS, and this further enhanced ROS level tumor cells <italic>via</italic> the Fenton reaction.
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...
Tumor microenvironment (TME), with complex composition, plays a vital role in the occurrence, development, and metastasis of tumors. TME becomes an important obstacle to accessibility nanotherapy, thus indicating need improve functional design overcome this challenge. In study, we generate intelligent nano-drug-delivery system (DOX@PssP-Hh NPs) dual environmental response, which involves heparanase (HPSE) glutathione (GSH) tumor cells. The nanosystem consists nanoskeleton formed by...
<p>List of common direct target genes BRD4 in KRAS-mutant NSCLC cells.</p>
<p>List of NSCLC cell lines with corresponding BRD4 mRNA levels and IC50 values for palbociclib.</p>
<p>List of supplementary data and Supplementary Figures 1-9.</p>
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...